Merkel Cell Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The merkel cell carcinoma market size was valued at USD 3.27 billion in 2025 and is estimated to grow from USD 3.47 billion in 2026 to reach USD 4.70 billion by 2031, at a CAGR of 6.27% during the forecast period (2026-2031). This report is Segmented by Disease Stage (Stage I, Stage II, Stage III), Modality (Diagnosis, Treatment), End User (Academic Cancer Centers, Hospital Oncology Departments, Office-Based Oncology and Infusion Centers, Reference Laboratories), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Merkel Cell Carcinoma Market Trends and Insights

Rising Elderly and Immunosuppressed Patient Population

The Merkel cell carcinoma market benefits from a rising patient base, particularly among older demographics where the disease is most prevalent. A review of 11,574 cases in the United States reported a median diagnosis age of 77 years, with diagnoses from 2016 to 2021 linked to improved survival rates, indicating better detection in older groups. Additionally, a 23.8-fold increased risk in solid organ transplant recipients and a 13.4-fold risk in untreated HIV-positive individuals highlight the market's reliance on high-risk immunosuppressed populations. This demand is further driven by the need for frequent monitoring and specialist care, ensuring sustained market growth despite the disease's rarity.

Checkpoint Inhibitors Entrenched in Treatment Guidelines

Checkpoint inhibitors have become the standard treatment for advanced Merkel cell carcinoma, replacing chemotherapy in major reimbursement settings. NCCN guidelines list pembrolizumab, avelumab, nivolumab, and retifanlimab as first-line options for unresectable or metastatic cases. Clinical studies show a median response duration of 39.8 months for pembrolizumab, with 36% of patients maintaining responses beyond 24 months. This shift ensures consistent treatment patterns and strengthens the market's commercial foundation in the United States, Europe, and select Asia-Pacific regions.

Tiny Incident Population And Trial Recruitment Bottlenecks

The Merkel cell carcinoma market faces challenges due to a limited patient pool for trials and specialized treatments. A 2025 epidemiology review in the United States reported an average incidence rate of 0.68 per 100,000 person-years since 2013, resulting in consistently low annual case counts. This restricts recruitment, centralizes studies in major cancer centers, and complicates evidence generation compared to common solid tumors. TuHURA Biosciences’ Phase 3 IFx-2.0 study, targeting 118 patients across 22 to 25 United States sites, highlights the significant infrastructure required for even modest trials. These bottlenecks delay pipeline turnover and concentrate innovation in a few centers, increasing execution risks for smaller companies.

Other drivers and restraints analyzed in the detailed report include:

• ctDNA-Guided Surveillance Expanding the Diagnostic Market
• Chemo-to-Immunotherapy Treatment Shift in Systemic Therapy
• High Biologic Cost And Reimbursement Scrutiny

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Stage III accounted for 44.45% of the Merkel cell carcinoma market size in 2025 and is projected to grow at a 7.28% CAGR through 2031, making it the largest and fastest-growing segment. This stage bridges local disease management and systemic immunotherapy, including patients with clinically positive nodes or nodal disease identified pathologically. NCCN Version 2.2026 recommends sentinel lymph node biopsy for clinically node-negative patients, improving detection and shifting some cases to Stage III. This shift enhances identification at a point where systemic therapy becomes relevant.

Stages I and II constitute the remaining disease-stage split, with revenue focused on surgery, sentinel node biopsy, radiation, and follow-up. These stages could gain value if adjuvant immunotherapy becomes routine. The STAMP pembrolizumab and ADAM avelumab trials, with results expected during the forecast period, may redirect early-stage revenue from radiation-only treatments to checkpoint inhibitors.

Complete Report Scope:

• By Disease Stage
  • Stage I
  • Stage II
  • Stage III
• By Modality
  • Diagnosis
    • Biopsy
    • Imaging
    • Others
  • Treatment
    • Surgery
    • Radiation Therapy
    • Chemotherapy
    • Targeted Therapy
    • Others
• By End User
  • Academic Cancer Centers
  • Hospital Oncology Departments
  • Office-Based Oncology and Infusion Centers
  • Reference Laboratories and Molecular Diagnostics Labs
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America dominates the Merkel cell carcinoma market, driven by high treatment adoption, advanced specialist infrastructure, and widespread guideline-based care. The United States leads this region with greater case visibility, extensive immunotherapy use, and a well-established referral system for rare skin cancers. NCCN guidance has standardized checkpoint inhibitor use for unresectable or metastatic diseases, while the 2025 update emphasized quarterly ctDNA surveillance in routine follow-ups. This combination of treatment access and monitoring depth secures North America's leading position in the market.

Europe ranks as the second-largest region in the Merkel cell carcinoma market, with Germany, the United Kingdom, and France as key revenue contributors. The region benefits from established checkpoint inhibitor use and multidisciplinary care pathways in specialized oncology and dermatology centers. Real-world registry data from German dermatologic oncology centers has strengthened clinical evidence in this rare-disease segment. However, intense reimbursement reviews in some markets may limit uptake outside major centers and affect biologics' pricing power.

Asia-Pacific is the fastest-growing region in the Merkel cell carcinoma market, with Japan, China, and Australia driving growth through diverse demand patterns. Japan prioritizes checkpoint inhibitors in care pathways, with chemotherapy as a secondary option. Regulatory familiarity with retifanlimab in Japan during 2025 highlights the potential for faster adoption of rare-cancer immunotherapies. Aging populations and expanding oncology infrastructure in urban centers further support the region's rapid growth trajectory, despite its smaller current market base compared to North America and Europe.

List of Companies Covered in this Report:

• AstraZeneca
• BioInvent International AB
• Bristol-Myers Squibb
• EMD Serono, Inc.
• FUJIFILM Pharmaceuticals U.S.A., Inc.
• ImmunityBio, Inc.
• Immunomic Therapeutics, Inc.
• Incyte
• Kartos Therapeutics, Inc.
• MacroGenics
• Merck
• Merck
• Natera, Inc.
• Ono Pharmaceutical
• Pfizer
• Replimune Group, Inc.
• Transgene
• TuHURA Biosciences, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support